EHA 2015 Multiple Myeloma Satellite Symposia
There will be seven multiple myeloma-related satellite symposia conducted in association with the 2015 European Hematology Association (EHA) annual meeting in Vienna, Austria. All symposia will take place on Thursday, June 11, which is the day prior to the official start of the meeting.
They symposia are generally sponsored by major pharmaceutical companies. They offer attendees the opportunity to hear leading myeloma-researchers share their perspectives on key myeloma-related issues.
Information about each of the seven satellite symposia is listed below.
The Beacon also has a list of the myeloma-related oral presentations that will take place at the 2015 EHA meeting.
In addition, the Beacon has two lists of the myeloma-related poster presentations that will take place at the EHA meeting. There is one list for the posters to be presented on Friday, June 12, and a second list for the posters to be presented on Saturday, June 13.
| Session |
Novartis - Understanding the Role of Epigenetics in the Pathogenesis and Treatment of Multiple Myeloma |
| Type | Satellite Symposium |
| Time | Thursday June 11, 8:00 AM to 10:00 AM |
| Location | Room A7 |
| Chair | H Einsele |
| H Einsele |
Welcome and Opening Remarks |
| F Prósper |
Introduction to Epigenetics and its Role in the Pathogenesis of Hematologic Malignancies |
| A Spencer |
Rationale for Targeting Epigenetic Mechanisms in Multiple Myeloma |
| J Cavenagh |
Clinical Update on Pan-Deacetylase Inhibitors in Multiple Myeloma |
| H Einsele |
Opportunities for Novel Combinations With Agents Targeting Epigenetic Mechanisms |
| H Einsele |
Panel Discussion |
| Session |
prIME Oncology - Relapsed/Refractory Multiple Myeloma: Embracing the Person in Personalized Care |
| Type | Satellite Symposium |
| Time | Thursday June 11, 8:00 AM to 10:00 AM |
| Location | Room C1 |
| Chair | A Palumbo |
| A Palumbo |
Keynote Lecture – Tailoring Therapy in Relapsed / Refractory Multiple Myeloma (MM): Balancing the Science with the Individual |
| M Dimopoulos |
Moving Forward with Immunomodulatory Agents in MM |
| Y Biru |
Patient Experience with Immunomodulatory Agents |
| J San-Miguel |
Progress in Proteasome Inhibition: Today and Tomorrow |
| Y Biru |
Patient Experience with Proteasome Inhibitors |
| P Richardson |
What lies ahead? Future Therapeutic Strategies |
| Y Biru |
Patient Experience Addressing What Lies Ahead |
| Panel |
Taking Next Steps: A Panel Discussion |
| Session |
Celgene - Taking Control of Myeloma: Continuous Advancements in Patient Care |
| Type | Satellite Symposium |
| Time | Thursday June 11, 10:45 AM to 12:45 PM |
| Location | Room A2+3 |
| Chair | H Ludwig |
| H Ludwig |
Welcome and Introduction |
| F Davies |
Immune Dysfunction and the Mechanism of Action of IMiDs |
| T Facon |
New Standard of Care for NDMM Patients Not-Eligible for Transplant |
| S Zweegman |
Practical Considerations for Your NDMM Patients |
| A Palumbo |
Emerging Combinations for the Treatment of RRMM |
| TBC |
Practical Considerations for Your RRMM Patients |
| H Ludwig |
Summary and Close |
| Session |
Janssen - Practical Management of Multiple Myeloma in a Changing Treatment Landscape |
| Type | Satellite Symposium |
| Time | Thursday June 11, 1:30 PM to 3:30 PM |
| Location | Room A2+3 |
| Chair | M Dimopoulos and T Facon |
| M Dimopoulos |
Diagnosing Myeloma in 2015 – Applying the Updated Diagnostic Criteria |
| H Einsele |
First Line Multiple Myeloma Therapy in 2015: Clinical Choices and Expert Opinion |
| T Facon |
Envisioning the Future: The Potential for Monoclonal Antibodies |
| Session |
Takeda - Shifting Paradigms in Multiple Myeloma: Future Insights to Practice |
| Type | Satellite Symposium |
| Time | Thursday June 11, 1:30 PM to 3:30 PM |
| Location | Strauss 1 |
| Chair | S Lonial |
| S Lonial |
Introduction |
| S Lonial |
The Changing View of Smoldering Myeloma: The Potential Impact of Treatment vs Observation |
| S Lonial |
Primary Induction Therapy in Multiple Myeloma: A Search for Best Practices - Panel Discussion |
| A Palumbo |
Transplant Therapy and Continuous / Maintenance Therapy: Rapidly Evolving Paradigms |
| J San-Miguel |
Relapsed / Refractory Disease Treatment and Management |
| S Lonial |
Closing Summary |
| Session |
Bristol-Myers Squibb - Immuno-Oncology: A New Era in Hematology Treatment? Research in Lymphoma and Myeloma |
| Type | Satellite Symposium |
| Time | Thursday June 11, 4:15 PM to 6:15 PM |
| Location | Room C1 |
| Chair | R Houot |
| R Houot |
Welcome and Introductions |
| R Houot |
Why Immuno-Oncology in Hematology? |
| M Shipp |
Potential Role of I-O in Lymphoma |
| P Moreau |
A New Era in Myeloma? |
| T Dimopoulos |
Potential Role of I-O in Myeloma |
| J Timmerman |
Targeting PD-1: A New Era in Lymphoma? |
| Session |
Amgen - Charting New Depths in the Treatment of Multiple Myeloma |
| Type | Satellite Symposium |
| Time | Thursday June 11, 4:15 PM to 6:15 PM |
| Location | Room C2 |
| Chair | J San-Miguel |
| J San-Miguel |
Chair's Welcome and Introduction |
| F Davies |
Choosing the Right Course – Identifying Myeloma Defining Events and Acting Accordingly |
| J San-Miguel |
Navigating the Heterogeneity of Myeloma – How Can We Individualize Treatment and Monitor Outcomes Most Effectively? |
| H Einsele |
What's on Our Radar – Strategies for Achieving the Deepest and Most Durable Responses in Newly Diagnosed Multiple Myeloma |
| A Jakubowiak |
Charting New Depths in the Treatment of Relapsed Multiple Myeloma |
| J San-Miguel |
Chair's Summary |
